<DOC>
	<DOCNO>NCT00935883</DOCNO>
	<brief_summary>To evaluate safety efficacy eculizumab treatment dry AMD evaluate change drusen volume area geographic atrophy .</brief_summary>
	<brief_title>Complement Inhibition With Eculizumab Treatment Non-Exudative Macular Degeneration ( AMD )</brief_title>
	<detailed_description>This randomize , double-arm , double-masked study design evaluate safety efficacy eculizumab treatment patient dry AMD . There three stage study : screening period , treatment period , follow-up period.During screening period patient evaluated eligibility . Eligible patient receive either eculizumab placebo 24 week . A total 60 patient enrol divide equally drusen cohort GA cohort . A 2:1 randomization result 20 patient cohort receive eculizumab 10 patient receive placebo . The treatment period begin two week administration meningococcal vaccine . During treatment period , patient receive eculizumab placebo period approximately 26 week . Patient treatment accord follow regimen : Induction Period : patient receive eculizumab 600 mg 900 mg via IV infusion approximately 30 minute week ( 7 ± 2 day ) 4 week follow 900 mg eculizumab fifth dose 7 day later ( 7 ± 2 day ) . Maintenance Period : patient receive eculizumab 900 mg 1200 mg via IV infusion approximately 30 minute every 2 week ( 14 ± 2 day ) . After final schedule dose eculizumab Placebo week 24 , patient return follow-up exam 2 week , 3 month , 6 month final dose .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 50 year In study eye ( ) , presence nonexudative AMD document fundus photography , autofluorescence , fluorescein angiography , spectral domain OCT . Visual acuity 20/63 better ( BCVA score least 59 letter ) measure ETDRS chart . Able willing comply study procedure . Visual acuity worse 20/63 Any history choroidal neovascularization study eye Unresolved meningococcal disease . Confounding ocular condition amblyopia ; aphakia ; myopia require &gt; 6 diopter correction ; pigment epithelial detachment ; uncontrolled glaucoma ( intraocular pressure ≥ 25 mmHg despite treatment antiglaucoma medication ) ; steroidinduced ocular hypertension ; retinal inflammatory disease ; central serous choroidopathy ; prior current retinal detachment ; macular edema ; cystic lesion ( individual cyst cystoid macular edema ) ; ocular herpes simplex virus ; severe nonproliferative bad diabetic retinopathy ; anterior ischemic optic neuropathy ; RPE tear involve macula ; pseudovitelliform macular degeneration ; vitreoretinal traction maculopathy ; vitreous hemorrhage , history current rhegmatogenous retinal detachment macular hole ; uveitis ; diffuse choroidal atrophy ; optic atrophy ( evidenced pallor ) ; intraocular inflammation ; ocular periocular infection ; moderate bad dry eye syndrome ; clinically significant cataract opacification posterior capsule , Investigator 's opinion , would progress course study could affect central vision ; ocular condition Investigator believe may confound factor study Refusal vaccinate Neisseria meningitides active Neisseria meningitides infection</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Age Related macular Degeneration</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>Drusen</keyword>
	<keyword>Geographic atrophy</keyword>
	<keyword>Eculizumab</keyword>
	<keyword>Soliris</keyword>
</DOC>